RxDoctor Payments Data

Thomas Wheeler, MD

Nephrology · Columbia, SCNPI 1154536506

Payments from drug & device makers

What this record shows

This record is dominated by food and beverage: $6,305 of the $8,628 with a category attached, or 73.1%. 40 manufacturers reported payments, led by Baxter Healthcare at 28.0% of the total.

$8,628in general payments, 2019–2025

Across 271 payments — averaging $31.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Baxter Healthcare$2K
  • AstraZeneca$961
  • Calliditas Therapeutics US Inc.$543
  • Amgen$524
  • Otsuka America Pharmaceutical, Inc.$394
  • Fresenius USA Marketing, Inc.$374
  • plus $3K from 34 others

What the payments were for

  • Speaking & faculty fees$1,76220%
  • Travel & lodging$5006%
  • Food & beverage$6,30573%
  • Education$621%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,628 in reported general payments places this provider in the 85th percentile of 180 nephrology providers in South Carolina.

See all nephrology providers in South Carolina

Medicare billing

Part B allowed, 2024
$202,972
Medicare patients
605
Services billed
4,622

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
VelphoroSucroferric Oxyhydroxide32$70,231
ProcritEpoetin Alfa69$43,289
FarxigaDapagliflozin Propanediol44$25,957
LokelmaSodium Zirconium Cyclosilicate19$13,984
EliquisApixaban14$10,068
Sevelamer Carbonate43$6,568
MyrbetriqMirabegron13$6,178
Labetalol Hcl36$1,075
Bumetanide19$1,055
Hydralazine Hcl53$937
Furosemide84$517
Calcitriol45$490
Irbesartan21$398
Allopurinol47$371
Metoprolol Succinate18$257

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Fresenius USA Marketing, Inc.Velphoro$374$70,23132 claims
Johnson & JohnsonProcrit$95$43,28969 claims
AstraZenecaFarxiga, Lokelma$961$39,94163 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 180 nephrology providers in South Carolina.

Other nephrology in Columbia

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →